Chronoscale Holdings Corp annual report, FY2020

Filing summary

Filing identity and period: The supplied filing is Ekso Bionics Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed February 25, 2021. This differs from the request metadata, which names Chronoscale Holdings Corp and describes the period as 2020 Q4.

Business context

Ekso designs, develops, sells and rents exoskeletons for medical rehabilitation and industrial applications. Its principal medical product is EksoNR; industrial offerings include EVO, introduced in August 2020. In June 2020, the FDA cleared EksoNR for use with acquired brain injury patients. The company reported more than 500 EksoGT and EksoNR units shipped to over 400 rehabilitation facilities or customers worldwide by year-end.

Financial performance and liquidity

Metric20202019
Revenue$8.9 million$13.9 million
Gross profit / margin$5.1 million / 57%$6.8 million / 49%
Operating loss$13.3 million$16.6 million
Net loss$15.8 million$12.1 million
Cash used in operating activities$8.8 million$15.8 million
Cash at year-end$12.9 million$10.9 million
  • Revenue fell 36%, driven primarily by lower medical-device sales amid COVID-related delays in customer capital spending. EksoHealth revenue was $8.1 million (2019: $12.0 million); EksoWorks revenue was $0.8 million (2019: $2.0 million).
  • Gross margin improved despite lower sales, which management attributed to higher EksoNR selling prices, product mix, lower unit production costs, EVO, and improved service margins.
  • Net loss worsened despite a narrower operating loss, largely because the company recorded a $3.1 million non-cash loss on warrant liabilities in 2020, versus a $6.4 million gain in 2019. Basic and diluted loss per share was $2.21, compared with $2.53.
  • Year-end working capital was $13.4 million. Balance-sheet notes payable, net, were $3.1 million; the Pacific Western Bank term loan was secured by substantially all assets other than intellectual property and required cash equal to outstanding principal. Approximately $2.0 million was subject to that liquidity covenant.
  • After year-end and through February 25, 2021, the company reported approximately $36.4 million in estimated net proceeds from a public offering, plus $1.4 million from warrant exercises and $0.7 million from ATM sales. Management said available cash, these proceeds and other actions supported funding operations beyond the one-year look-forward period.

Material changes, outlook and risks

  • Bookings for EksoGT and EksoNR were 61 units in 2020, down from 98 in 2019. Management cited restricted facility access, delayed purchasing and limits on in-person demonstrations due to COVID-19.
  • The company reduced its workforce by approximately 35% in a restructuring completed in May 2020, recording $0.2 million in severance costs, and recorded a $0.2 million goodwill impairment that reduced goodwill to zero.
  • The China joint venture was terminated after CFIUS concluded its national-security concerns could not be mitigated. The company recorded a $0.1 million loss related to previously incurred JV costs.
  • Management provided no quantified revenue, earnings or margin guidance. It planned continued investment in medical-market sales, rehabilitation product development and industrial products, while warning that additional financing might be needed and could dilute shareholders.
  • Key risks include ongoing losses and cash needs, COVID-related demand and sales-cycle uncertainty, limited adoption of a developing market, competition, regulatory and product-liability exposure, foreign-exchange risk, and potential dilution from equity and warrant issuance. Warrants accounted for as liabilities were valued using significant unobservable inputs, making reported earnings sensitive to share-price changes.
  • The financial statements received an unqualified audit opinion. Revenue recognition was identified as a critical audit matter. The auditor did not attest to internal control effectiveness; management reported its controls were effective as of year-end.

Key facts for investors to verify

  • Whether post-year-end financing and subsequent cash use provide adequate runway, taking account of restricted cash, debt payments and operating burn.
  • Whether bookings, device shipments and recurring rental and service revenue recover from 2020 levels, particularly in EksoHealth.
  • Whether the improved gross margin is sustainable as product mix, unit volumes and service costs change.
  • The potential dilution and earnings volatility associated with outstanding warrants, options and future equity offerings.
  • Progress on FDA-cleared indications, clinical evidence, commercial adoption and industrial partnerships, as well as the continuing effects of COVID-19.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.